Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20337805 | 1.00 | MTNR1A (0.42) | MTNR1AMTNR1BCARM1PRMT6MKNK2 | |
| SCHEMBL20337803 | 1.00 | MTNR1A (0.42) | MTNR1AMTNR1BCARM1PRMT6MKNK2 | |
| Hydrochloric Acid SCHEMBL20359067 | 0.99 | MTNR1A (0.41) | MTNR1AMTNR1BCARM1PRMT6MKNK2 | |
| Hydrochloric Acid SCHEMBL20359062 | 0.99 | MTNR1A (0.41) | MTNR1AMTNR1BCARM1PRMT6MKNK2 | |
| Hydrochloric Acid SCHEMBL20359065 | 0.99 | MTNR1A (0.41) | MTNR1AMTNR1BCARM1PRMT6MKNK2 | |
| SCHEMBL29293383 | 0.84 | MKNK2 (0.49) | MTNR1AMTNR1BMKNK2 | |
| SCHEMBL22978880 | 0.84 | MKNK2 (0.49) | MTNR1AMTNR1BMKNK2 | |
| SCHEMBL18376030 | 0.84 | MKNK2 (0.49) | MTNR1AMTNR1BMKNK2 | |
| Hydrochloric Acid SCHEMBL30579496 | 0.83 | MKNK2 (0.48) | MTNR1AMTNR1BCARM1PRMT6MKNK2 | |
| SCHEMBL2402576 | 0.82 | MTNR1A (0.44) | MTNR1AMTNR1BMKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397665-A2 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3319969-B1 | DIARYL MACROCYCLE POLYMORPH | TURNING POINT THERAPEUTICS INC (US) | 2024-04-03 | — | — | EP | disclosed |
| US-20230295184-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2023-09-21 | — | — | US | disclosed |
| US-11008337-B2 | Chiral diaryl macrocycles as modulators of protein kinases | Turning Point Therapeutics, Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210094974-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2021-04-01 | — | — | US | disclosed |
| WO-2021027503-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND INTERMEDIATE AND USE THEREOF | 罗欣药业(上海)有限公司 | 2021-02-18 | — | — | WO | disclosed |
| EP-3317285-B1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20190284209-A1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2019-09-19 | — | — | US | disclosed |
| US-20190233437-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2019-08-01 | — | — | US | disclosed |
| US-10316044-B2 | Chiral diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10294242-B2 | Diaryl macrocycle polymorph | TP THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180194777-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-20180186813-A1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186813-A1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, DAPK2 | MTNR1A 3665/4885MTNR1B 3400/4885CARM1 1475/4885 |
| US-10294242-B2 | Diaryl macrocycle polymorph | PKD1, CYP7B1, BRCA1 | MTNR1A 2240/4885MTNR1B 1511/4885CARM1 4355/4885 |
| US-20190284209-A1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, DAPK2 | MTNR1A 3665/4885MTNR1B 3400/4885CARM1 1475/4885 |
| US-10316044-B2 | Chiral diaryl macrocycles as modulators of protein kinases | LCK, MAP3K20, MAP3K1 | MTNR1A 3151/4885MTNR1B 2862/4885CARM1 1685/4885 |
| US-11008337-B2 | Chiral diaryl macrocycles as modulators of protein kinases | LCK, MAP3K20, MAP3K19 | MTNR1A 3173/4885MTNR1B 2915/4885CARM1 1665/4885 |
| US-20180194777-A1 | DIARYL MACROCYCLE POLYMORPH | PKD1, CYP7B1, BRCA1 | MTNR1A 2240/4885MTNR1B 1511/4885CARM1 4355/4885 |
| US-20190233437-A1 | DIARYL MACROCYCLE POLYMORPH | PKD1, CYP7B1, BRCA1 | MTNR1A 2240/4885MTNR1B 1511/4885CARM1 4355/4885 |
| US-20210094974-A1 | DIARYL MACROCYCLE POLYMORPH | PKD1, CYP7B1, BRCA1 | MTNR1A 2240/4885MTNR1B 1511/4885CARM1 4355/4885 |
| US-20230295184-A1 | DIARYL MACROCYCLE POLYMORPH | PKD1, CYP7B1, BRCA1 | MTNR1A 2240/4885MTNR1B 1511/4885CARM1 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.